together with our patients, we strive to extend survival in some of the most aggressive forms of cancer
about us
our therapy
our pipeline
careers
news and media
investor relations
NEWS
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.
patient forward
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.